Differential expression of histone demethylase KDM3B and JMJD1C in acute myeloid leukemia
10.3969/j.issn.1005-1678.2017.01.006
- VernacularTitle:急性髓系白血病中组蛋白去甲基化酶KDM3B和JMJD1C的差异化表达
- Author:
Wen QU
;
Xin XU
;
Yao ZHAO
;
Zhenbo HU
- Keywords:
acute myeloid leukemia;
histone modifying enzymes;
KDM3B;
JMJD1C
- From:
Chinese Journal of Biochemical Pharmaceutics
2017;37(1):27-30
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the synergistic regulation of KDM3B and JMJD1C in leukemia. Methods The expression level of JMJD1C and KDM3B were analyzed in multiple acute myeloid leukemia (AML) cell lines. AML cell lines NB4 and HL-60 were treated with Daminozide, followed by determination of H3K9 mono-methylation and di-methylation. AML cell lines NB4 and HL-60 were treated with Daminozide, ATRA (retinoid acid All-trans), C Vitamin and the expression of KDM3B and JMJD1C were detected by real-time quantitative PCR. Results The expression level of KDM3B and JMJD1C in the AML cell lines was negatively correlated. In NB4 and HL-60 cells treated by daminozide, H3K9 mono-methylation and di- methylation level showed a rising trend in these two cell groups. After treatment of NB4 cells with the 3 reagents, the level of mRNA of KDM3B was down-regulated while the level of mRNA of JMJD1C was up-regulated. In HL-60 cells treated by daminozide, the mRNA level of KDM3B was up-regulated and the mRNA level of JMJD1C was down-regulated. Conclusion The expression of KDM3B and JMJD1C is negatively correlated in patients with AML.